China Resources Double-Crane Pharmaceutical Co (SHSE:600062) YoY EBITDA Growth : 10.13% (As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is China Resources Double-Crane Pharmaceutical Co YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. China Resources Double-Crane Pharmaceutical Co's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 10.13%.

China Resources Double-Crane Pharmaceutical Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.50.

China Resources Double-Crane Pharmaceutical Co YoY EBITDA Growth Historical Data

The historical data trend for China Resources Double-Crane Pharmaceutical Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Double-Crane Pharmaceutical Co YoY EBITDA Growth Chart

China Resources Double-Crane Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

6.05

-2.37

0.52

26.37

12.24

China Resources Double-Crane Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															12.38	-8.67	15.91	46.52	10.13

China Resources Double-Crane Pharmaceutical Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

China Resources Double-Crane Pharmaceutical Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(2.173	-	1.936)	/	\| 1.936 \|
=	12.24 %

China Resources Double-Crane Pharmaceutical Co's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(0.5	-	0.454)	/	\| 0.454 \|
=	10.13 %

China Resources Double-Crane Pharmaceutical Co YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of China Resources Double-Crane Pharmaceutical Co's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Double-Crane Pharmaceutical Co Ltd (SHSE:600062) » Definitions » YoY EBITDA Growth

Traded in Other Exchanges

N/A

Address

No. 1, East Second Road, Lijing, Wangjing, Chaoyang District, Beijing, CHN, 100102

Website

http://www.dcpc.com

China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.

China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Headlines

No Headlines